Modality
Oral peptide/small molecule peptide
Non-peptide small molecules or peptide formulations designed for oral bioavailability, including SNAC-enabled peptides.
Examples
- Oral semaglutide
- Danuglipron
- Orforglipron
- GSBR-1290
- Lotiglipron
Related assets
View all →| Asset | Stage | Mechanism |
|---|---|---|
| Danuglipron | Phase 2 | Oral small-molecule GLP-1 receptor agonist being evaluated in twice-daily and once-daily formulations. |
| Lotiglipron | Discontinued | Once-daily oral small-molecule GLP-1 receptor agonist discontinued after phase 2 due to liver enzyme elevations. |
| GSBR-1290 | Phase 2 | Orally bioavailable small-molecule GLP-1 receptor agonist discovered using structure-based design. |
| Orforglipron | Phase 3 | Oral small-molecule GLP-1 receptor agonist advanced by Eli Lilly into phase 3 for obesity and type 2 diabetes. |
| Oral semaglutide | Approved | SNAC-enabled oral formulation of semaglutide providing GLP-1 receptor agonism via the gut. |